by Jordana Choucair | Dec 8, 2022 | Life Sciences
Pfizer and Moderna announced that the commercial prices of their COVID-19 vaccines will likely be between $82 and $130 per dose. The cost is approximately three to four times what the federal government has paid. The Biden administration has started to prepare for the...
by Jordana Choucair | Dec 2, 2022 | Life Sciences
Pfizer Inc. plans to invest more than $2.5 billion in manufacturing plants in Belgium and Ireland. The company hopes that developing new products will offset losses from expiring patents and declining COVID-19 vaccine sales. (Article here)
by Jordana Choucair | Dec 2, 2022 | Life Sciences
Merck & Co. could maintain patents for its best-selling drug Keytruda by patenting an injectable form of the medicine, which it’s currently testing in clinical trials. Certain patents for Keytruda are up in 2028, when copies of the drug could hit the market....
by Jordana Choucair | Nov 30, 2022 | Life Sciences
Eisai Co. Ltd. and Biogen Inc.’s Alzheimer drug lecanemab slowed patients’ mental decline by 27 percent over 18 months, according to a trial presented at the Clinical Trials on Alzheimer’s Disease conference. However, more than one in five people...
by Jordana Choucair | Nov 29, 2022 | Life Sciences
Research published in JAMA Internal Medicine revealed that Food and Drug Administration (FDA) approvals of “skinny labels” on biosimilars saved Medicare over $1 billion over five years. According to the research, the FDA approved 33 biosimilars based on 11...
by Jordana Choucair | Nov 23, 2022 | Life Sciences
The Food and Drug Administration (FDA) approved Hemgenix, an IV treatment for adults with hemophilia B. Shortly after the approval, Drugmaker CSL Behring announced that the drug costs $3.5 million a dose, making it the most expensive medicine in the world. CSL Behring...
Recent Comments